AstraZeneca Boosts Respiratory Business with US$2.1 B Almirall Deal
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 9 (Table of Contents)
Published: 13 Sep-2014
DOI: 10.3833/pdr.v2014.i9.2061 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a surprise move that prompted the company’s shares to jump by 8%, Almirall has agreed to sell its entire respiratory franchise to AstraZeneca for up to US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS